Skip to content
Hair Pipeline
← Back to the pipeline

VDPHL-01 (oral minoxidil)

VDPHL-01 (oral minoxidil) is in Phase 3 for androgenetic alopecia, developed by Veradermics.

An extended-release oral minoxidil tablet, taken through registration-directed trials for an approval that oral minoxidil has never had for hair loss.

Monthly digest of verified phase changes. A confirmation link goes out first; unsubscribe is one click on every mail.

Developed by
Veradermics
Current phase
Phase 3

Large confirmatory trials. The last step before filing.

Mechanism
Potassium channel opener

Opens potassium channels in the follicle - minoxidil's mechanism, thought to improve blood flow and prolong the growth phase.

Also known as
VDPHL01
Last public activity
August 2026
Copy last reviewed
October 2026
Record confidence
Medium

A research record, not medical advice: being listed here says nothing about whether a treatment works or whether it is right for you. Talk to a dermatologist about your own case.

Why it matters

Dermatologists prescribe low-dose oral minoxidil off-label, and randomised trials of it have been published, including a 2024 JAMA Dermatology trial where 5 mg daily was not superior to the topical. What has never existed is a formulation studied for an approved hair-loss label: VDPHL01 is Veradermics's extended-release tablet, 8.5 mg once or twice daily in men and 4.5 mg in women, designed to avoid the peaks of immediate-release minoxidil. Both placebo-controlled trials in men have reported six-month results the company calls positive (the Phase 2/3 '302' in 519 men in April 2026, the Phase 3 '304' in 536 men in October 2026). No marketing application has been announced, in the US or Europe. The next readouts the company has announced are the twelve-month '302' data later in 2026 and the women's '306' study in the first half of 2027; the registered December 2026 completion of the men's Phase 3 refers to a trial already reported at six months. The programme's point is a label, which off-label prescribing cannot supply; until the data are published, the numbers are the sponsor's.

Development history

  1. Phase 2/3Phase 3

    First Phase 3 trial on record: NCT06972264 — Safety and Efficacy of VDPHL01 in Males With AGA

    ClinicalTrials.gov ↗
  2. Phase 2Phase 2/3

    First Phase 2/3 trial on record: NCT06724614 — Efficacy and Safety of VDPHL01 in Males With AGA

    ClinicalTrials.gov ↗
  3. Phase 2

    First Phase 2 trial on record: NCT06527365 — Safety and Efficacy of VDPHL01 in Males and Females With AGA

    ClinicalTrials.gov ↗

Registered trials

Pulled automatically from ClinicalTrials.gov. Matching is by name and development code, so occasional gaps are possible — tell us if you spot one.

  • NCT07146022Phase 3Active, not recruiting

    Safety and Efficacy of VDPHL01 in Females With Androgenetic Alopecia (AGA)

    Veradermics, Inc. · n=552 · July 2025

  • NCT06972264Phase 3Active, not recruiting

    Safety and Efficacy of VDPHL01 in Males With AGA

    Veradermics, Inc. · n=480 · March 2025

  • NCT06724614Phase 2/3Active, not recruiting

    Efficacy and Safety of VDPHL01 in Males With AGA

    Veradermics, Inc. · n=480 · November 2024

  • NCT06527365Phase 2Active, not recruiting

    Safety and Efficacy of VDPHL01 in Males and Females With AGA

    Veradermics, Inc. · n=70 · July 2024

Listing a trial is not a recommendation to join one. Eligibility, risks and costs vary enormously — discuss any trial with your own doctor first.

Sources

Related programmes

Other programmes in the register with the same mechanism: Potassium channel opener.

Cite this page

Hair Pipeline, "VDPHL-01 (oral minoxidil) — development record", hairpipeline.com/pipeline/vdphl-01